Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomma Lab InternacionalB de CV (MEX:LABB) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Genomma Lab InternacionalB de CV Future 3-5Y EPS without NRI Growth Rate Related Terms
MEX:LABB vs ZTS, UTHR, VTRS: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 10.52 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Future 3-5Y EPS without NRI Growth Rate of 10.52 as of Sep. 12, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Genomma Lab InternacionalB de CV and its competitors. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #160 out of 231 companies in the Drug Manufacturers industry, placing it in the top 69.3%.
Is Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate too high?
Genomma Lab InternacionalB de CV's current Future 3-5Y EPS without NRI Growth Rate is 10.52. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 17.15. Genomma Lab InternacionalB de CV's value of 10.52 is 38.7% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #160 out of 231 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Future 3-5Y EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #160 out of 231 companies for Future 3-5Y EPS without NRI Growth Rate. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.15. Genomma Lab InternacionalB de CV's value of 10.52 is 38.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 17.15, based on 231 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Future 3-5Y EPS without NRI Growth Rate of 10.52 is 38.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Future 3-5Y EPS without NRI Growth Rate is 10.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.29, compared to a current price of MXN12.67 — trading 26.7% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 10.52 and 38.7% below the Drug Manufacturers industry median of 17.15. Genomma Lab InternacionalB de CV's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Future 3-5Y EPS without NRI Growth Rate is 10.52 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN12.67 is trading 26.7% below its estimated GF Value™ of MXN17.29.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Future 3-5Y EPS without NRI Growth Rate: 10.52
GF Value™: MXN17.29 vs. price of MXN12.67 (26.7% below fair value)
Industry Position: 38.7% below the Drug Manufacturers median (#160 of 231)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
64GF Score
Get the complete analysis for MEX:LABB
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
